Five checks catch nearly every surprise: whether the drug still sits on the current drug list, at what tier, whether the authorization rules were revised, whether an existing approval is still valid, and where the deductible now stands. Run them at the plan’s renewal date, which for employer coverage is frequently not January 1.
The plan year and the calendar year are often different
Employer coverage renews on the anniversary of the group contract. That can be July, October, or any other month, and it is the date on which drug lists, cost sharing and authorization rules can all change at once. People who assume a January reset get caught in the spring or the fall instead.
The renewal date appears on the summary of benefits and coverage. It is worth knowing precisely, because every other item on this list keys off it. Individual marketplace plans and Medicare drug plans do run on the calendar year, which is why advice written for one market misleads people in the other.
What changes and when
| What can change | Typical timing | How it shows up |
|---|---|---|
| Drug list additions and removals | Annual, sometimes quarterly | Claim rejects as non-formulary |
| Tier placement | Annual renewal | Same drug, higher copay or coinsurance |
| Authorization criteria | Annual, occasionally mid-year | Renewal denied on rules that changed |
| Existing approval expiring | 6 or 12 months from issue | Reject citing no authorization on file |
| Deductible and out-of-pocket reset | Start of the plan year | Full price until the deductible is met |
| Pharmacy channel rules | Annual renewal | Retail fill refused, mail or specialty required |
Mid-year drug list revisions are real
Drug lists are living documents. Removals, tier moves and new restrictions can be applied between renewals, and plans generally commit to giving advance notice of negative changes rather than to never making them. For a class as expensive and fast moving as GLP-1 medication, mid-year revisions are more likely than in a settled therapeutic area.
The practical habit is to check the drug list attached to the member ID rather than a generic list published on a public page. Large insurers maintain many separate lists, and the one that governs a specific person is the one their plan selected.
Tracking these moving parts is easier with a plain-language reference nearby. Providers including LillyDirect, Henry Meds, and HealthRX maintain public pages for patients, and the HealthRX writeup on GLP-1 insurance coverage explains formulary tiers, prior authorization, and the mid-year changes that catch people out. Checking one against the plan’s own annual notice makes an unexpected tier move or rejection easier to place.
An approval does not automatically survive a renewal
This is the single most common mid-year failure. An authorization granted in March under one set of criteria can expire in September, and the renewal request is then measured against whatever rules apply at that moment. If the criteria tightened, a person who has been stable on the drug for six months can be refused.
Renewal requests for weight management drugs commonly ask for evidence of response, so the record needs recent documented weights. Where a plan requires continued benefit to maintain approval, missing measurements can defeat a request that the clinical picture would otherwise support. Continued treatment is what sustains the effect in trials of both semaglutide and tirzepatide, and withdrawal studies show regain follows discontinuation, so an administrative gap has a clinical cost.
A deductible reset is not a coverage change
Every plan year the deductible starts again. A person paying a modest copay in December can face the full negotiated price in January while the drug is still perfectly well covered. The pharmacy experience is alarming and the cause is arithmetic rather than policy.
High deductible plans paired with a health savings account produce the largest version of this. Planning for the first quarter of the plan year, rather than assuming the December figure repeats, is what keeps treatment continuous. Medicare drug coverage now has an annual out-of-pocket limit that is indexed each year, which changes the shape of the same problem for Part D members.
Copay assistance may not count toward the deductible
Many plans operate accumulator or maximizer programs, under which manufacturer copay card dollars do not apply to the member’s deductible or out-of-pocket maximum. The card still reduces the counter price, but the member reaches their own limits far later than the spending suggests. This design is widespread for high cost specialty drugs and is easy to miss until a mid-year statement does not add up.
Rechecking on a schedule beats reacting
Sixty days before the renewal date, pull the new drug list and the current criteria document. Thirty days before an authorization expires, ask the prescribing office to file the renewal with recent weights attached. At the start of each plan year, confirm the pharmacy channel and the deductible position before the first fill rather than at the counter.
Pricing the fallback in advance turns a bad month into a planned decision. Manufacturer direct-pay programs publish cash figures for the branded products, and some people bridge a gap with a compounded GLP-1 provider instead. Compounded semaglutide and tirzepatide are prepared by compounding pharmacies and are not FDA-approved products, and the agency has stated that the shortages that originally justified compounding these molecules at scale were resolved, so anyone weighing that option should treat the regulatory position as changeable rather than settled.
Medicare members have a fixed annual rhythm
Part D and Medicare Advantage drug plans send an annual notice of change ahead of the fall enrollment window, and that document lists next year’s drug list and cost sharing. Reading it is the one reliable way to learn that a drug is moving tier or leaving the list before it happens. The enrollment window that follows is the only routine opportunity to switch plans, absent a qualifying special enrollment period.
Frequently asked questions
How much notice is given before a drug is removed from a list?
It varies by plan, market and the type of change. Plans generally commit to advance notice for negative changes affecting current users, and Medicare drug plans operate under specific federal notice rules. The plan document and the annual notice of change are where the applicable terms appear.
Does a new employer plan carry over an existing authorization?
Usually not. A new plan means new criteria and, in most cases, a new request. Building in several weeks before the switch date, with recent documentation ready, prevents a gap between the last fill on the old plan and the first on the new one.
Why did the price jump without any letter arriving?
The most frequent cause is a deductible reset at the start of the plan year, which changes what a member pays without changing whether the drug is covered. A tier move produces a similar jump and would normally be reflected in renewal materials.
What is a transition supply?
Medicare drug plans must provide a temporary fill in defined situations, such as a new enrollee already taking a drug that is not on the new plan’s list. It buys time to file an exception request rather than granting ongoing coverage, and the qualifying circumstances are narrow.
Is switching plans at open enrollment a reliable fix?
Only when an alternative genuinely covers the category. For employer coverage the choice is limited to what the employer offers, and if every option excludes anti-obesity medication, switching changes nothing. Comparing the drug lists rather than the premiums is what answers this.
